Professor Lei Fan: Internal Medicine Treatment and Research Progress of Ocular Lymphoma | First Academic Forum of the Ocular Lymphoma Collaboration Group

Professor Lei Fan: Internal Medicine Treatment and Research Progress of Ocular Lymphoma | First Academic Forum of the Ocular Lymphoma Collaboration Group

2024.05.12
On March 30, 2024, the First Academic Forum of the Ocular Lymphoma Collaboration Group was successfully held in Beijing. It was hosted by Beijing Tongren Hospital affiliated with Capital Medical University, China Human Health Technology Promotion Association, Beijing Public Health Science Popularization Promotion Association, and Beijing Chen Jumei Charity Foundation. The event was organized by the Cell Immunotherapy Committee of the China Human Health Technology Promotion Association. Renowned experts and scholars from both domestic and international communities actively exchanged ideas and engaged in discussions about the latest advancements and hot topics in the diagnosis and treatment of ocular lymphoma. Professor Lei Fan from Jiangsu Provincial People's Hospital was specially invited by "Oncology Frontier - Hematology Frontier" to share updates in the research on improving prognosis, novel biomarkers, and prevention of recurrence in the internal medicine treatment of ocular lymphoma.
Comparison of autologous,matched sibling,andalternative donor stem cell transplant outcomes for acute myeloid leukemia patients in first remission: A propensity score matching study

Comparison of autologous,matched sibling,andalternative donor stem cell transplant outcomes for acute myeloid leukemia patients in first remission: A propensity score matching study

2024.03.19
In September 2023, a pivotal study led by professor Erlie Jiang from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science was published in Hematology, focusing on acute myeloid leukemia (AML) patients in their first remission and comparing outcomes between autologous, matched sibling, and alternative donor stem cell transplants. This research innovatively applied propensity score matching to dissect and evaluate the nuances of transplant efficacy and safety across different donor types. By conducting a thorough and detailed comparison, Jiang and her collaborative team have markedly advanced the understanding of optimal transplant strategies for AML treatment. Their work illuminates the path toward enhancing patient survival rates and quality of life through informed donor selection, underscoring the study’s significance in the realm of personalized AML care. Through this study, Erlie Jiang and her colleagues have made a substantial contribution to refining clinical decision-making in the selection of stem cell transplant donors for AML patients.
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma

Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma

2024.03.14
In January 2024, a study led by Professor Gang An from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——American Journal of Hematology(IF=12.8). The title of the study is "Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma". This study represents a significant leap forward in precision medicine for multiple myeloma (MM).
WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

2024.01.19
The Paul A. Bunn, Jr. Scientific Award, bestowed by IASLC, aims to honor the lifelong scientific contributions of IASLC scientists to thoracic cancer research. Dr. Ramalingam's research focuses on developing new treatment strategies for lung cancer patients. His team developed innovative treatment regimens for lung cancer patients with EGFR mutations, which led to the FDA's approval of a third-generation EGFR inhibitor for metastatic non-small cell lung cancer. Additionally He also led clinical and translational research on new immunotherapies for treating lung cancer , resulting in over 400 published, peer-reviewed publications. He also served on the IASLC board of directors (2017-2021) and the NCI Thoracic Malignancy Steering Committee (2012-2021). He is currently the chief editor of the journal 《Cancer》 published by the American Society of Clinical Oncology.
AASLD Interview | Professor Fengmin Lu: Exploring Interferon Cure Advantages in Chronic Hepatitis B, Delving into Mechanisms to Guide New Drug Development

AASLD Interview | Professor Fengmin Lu: Exploring Interferon Cure Advantages in Chronic Hepatitis B, Delving into Mechanisms to Guide New Drug Development

2023.12.25
At the just-concluded Annual Summit of Hepatology, the American Association for the Study of Liver Diseases (AASLD2023), Professor Fengmin Lu's team from Peking University presented three contributions (1 oral presentation and 2 posters), focusing on the mechanisms related to chronic HBV infection. Their research revealed populations benefiting from interferon therapy in chronic Hepatitis B (CHB) and explored potential new targets for curing. "Hepatology Digest" has specially invited Professor Fengmin Lu to interpret the research findings, their significance and implications for future scientific research or clinical practice, and to envision the prospects for functional cure among the CHB population in our country.
Pay attention to the comorbidities of the heart, lungs, and metabolic system in HIV infected individuals

Pay attention to the comorbidities of the heart, lungs, and metabolic system in HIV infected individuals

2023.12.08
Anti retroviral therapy (ART) significantly improves the life expectancy of HIV infected individuals. However, in recent years, the incidence rate of cardiovascular diseases and other complications related to obesity, type 2 diabetes, and metabolic syndrome (namely, abdominal obesity, hypertension, elevated triglyceride levels, dyslipidemia, and changes in blood glucose levels) has gradually increased among HIV infected people, which has become a growing concern. The complex interaction between sustained low-level immune activation, ART related metabolic toxicity, and non HIV related risk factors in chronic HIV infection may increase the risk of these comorbidities in HIV infected individuals. At the 19th European Conference on AIDS (EACS 2023), Professor Susanne Dam Nielsen of the University of Copenhagen, Denmark, made a special report on the study of non infectious complications among HIV infected people, focusing on the latest research progress of cardiovascular disease, pulmonary disease and metabolic system disease complications. Our reporter invited Professor Nielsen to conduct an in-depth interview on this topic at the conference.